ADVaNCE | ADVerse outcome Network for non-mutagenic CarcinogEns

Summary
The field of toxicology is evolving from purely descriptive to a highly data‐rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outcome pathways was established providing a means of understanding how chemicals induce adverse effects through their toxicity pathways and modes of action. However, there are some doubts if the one initiating event - one adverse outcome relationship enforced on AOPs by the OECD guideline is able to cover more complex adverse effects like hepatocellular carcinoma resulting from non-mutagenic chemical exposure. Therefore, the ADVaNCE project will demonstrate based on the just mentioned example that combining all existing knowledge into an adverse outcome network formed by interlinked AOPs is needed to cover all the pathways and intervention points activated in order to contribute to the development of hepatocellular carcinomas. Computational approaches will be used to extract important key events and their relationships from existing data sources and the relevant literature. These will be compared with existing AOPs and further experimental validation will be started. The computational and experimental result will finally guide the development of an integrated testing strategy completely based on in silico and in vitro data, which development and validation regarding regulatory usage will be continued after the project.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/750195
Start date: 01-10-2017
End date: 30-09-2019
Total budget - Public funding: 187 419,60 Euro - 187 419,00 Euro
Cordis data

Original description

The field of toxicology is evolving from purely descriptive to a highly data‐rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outcome pathways was established providing a means of understanding how chemicals induce adverse effects through their toxicity pathways and modes of action. However, there are some doubts if the one initiating event - one adverse outcome relationship enforced on AOPs by the OECD guideline is able to cover more complex adverse effects like hepatocellular carcinoma resulting from non-mutagenic chemical exposure. Therefore, the ADVaNCE project will demonstrate based on the just mentioned example that combining all existing knowledge into an adverse outcome network formed by interlinked AOPs is needed to cover all the pathways and intervention points activated in order to contribute to the development of hepatocellular carcinomas. Computational approaches will be used to extract important key events and their relationships from existing data sources and the relevant literature. These will be compared with existing AOPs and further experimental validation will be started. The computational and experimental result will finally guide the development of an integrated testing strategy completely based on in silico and in vitro data, which development and validation regarding regulatory usage will be continued after the project.

Status

CLOSED

Call topic

MSCA-IF-2016

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2016
MSCA-IF-2016